Horizon Therapeutics (HPTX) & Kalvista Pharmaceuticals (KALV) Critical Review

Horizon Therapeutics (NASDAQ: HPTX) and Kalvista Pharmaceuticals (NASDAQ:KALV) are both small-cap biopharmaceuticals companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, profitability, risk, dividends, earnings and analyst recommendations.

Analyst Ratings

This is a summary of current ratings and price targets for Horizon Therapeutics and Kalvista Pharmaceuticals, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Horizon Therapeutics 0 0 0 0 N/A
Kalvista Pharmaceuticals 0 0 1 0 3.00

Kalvista Pharmaceuticals has a consensus target price of $27.00, suggesting a potential upside of 179.21%. Given Kalvista Pharmaceuticals’ higher possible upside, analysts plainly believe Kalvista Pharmaceuticals is more favorable than Horizon Therapeutics.

Institutional & Insider Ownership

60.2% of Kalvista Pharmaceuticals shares are held by institutional investors. 49.1% of Kalvista Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.


This table compares Horizon Therapeutics and Kalvista Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Horizon Therapeutics 23.13% 21.30% 15.42%
Kalvista Pharmaceuticals -1,379.58% -70.20% -63.10%

Valuation and Earnings

This table compares Horizon Therapeutics and Kalvista Pharmaceuticals’ gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Horizon Therapeutics N/A N/A N/A ($0.03) -1,533.00
Kalvista Pharmaceuticals $1.50 million 69.50 -$18.60 million ($2.44) -3.96

Horizon Therapeutics has higher earnings, but lower revenue than Kalvista Pharmaceuticals. Horizon Therapeutics is trading at a lower price-to-earnings ratio than Kalvista Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.


Kalvista Pharmaceuticals beats Horizon Therapeutics on 6 of the 10 factors compared between the two stocks.

Horizon Therapeutics Company Profile

Horizon Therapeutics, Inc., formerly Hyperion Therapeutics, Inc., is a biopharmaceutical company. The Company is engaged in the development and commercialization of therapeutics to treat disorders in the areas of orphan diseases. The Company’s products include RAVICTI (glycerol phenylbutyrate) oral liquid, BUPHENYL and AMMONAPS (sodium phenylbutyrate) tablets and powder. The Company’s products are used to lower ammonia in the blood. RAVICTI is used to treat urea cycle disorders (UCD). BUPHENYL is indicated as an adjunctive therapy in the chronic management of patients with UCDs involving deficiencies of carbamylphosphate synthetase (CPS), ornithine transcarbamylase (OTC), or argininosuccinic acid synthetase (AS). The Company sells BUPHENYL under the brand name AMMONAPS in Europe and the Middle East.

Kalvista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc., formerly Carbylan Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The Company has developed a portfolio of small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME). The Company is developing a plasma kallikrein inhibitor, which is administered directly into the eye. The Company is engaged in advancing several product candidates developed from its portfolio into early clinical trials. The Company is progressing additional oral candidates towards regulatory preclinical studies. The Company’s HAE product candidate, KVD818, is an inhibitor of plasma kallikrein. The Company has initiated clinical testing of KVD818 in a Phase I clinical trial. It has completed an open-label single ascending dose Phase I trial in DME patients with KVD001.

Receive News & Ratings for Horizon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply